NDANASALSPRAY, METERED
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Clinical Trials (5)
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
Started Sep 2025
0Migraine
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Started May 2025
16 enrolled
Acute Treatment of Migraine
A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women
Started Jun 2024
12 enrolled
Healthy
A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants
Started Oct 2023
13 enrolled
Healthy
A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling
Started Jul 2023
14 enrolled
Healthy
Loss of Exclusivity
LOE Date
Oct 7, 2031
68 months away
Patent Expiry
Oct 7, 2031
Exclusivity Expiry
Mar 9, 2028
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8481546 | Oct 7, 2031 | SubstanceProduct | U-3555 |